Markets

Top Stock Reports for Oracle, Allergan & Abbott

An image of a pen and a calculator
Credit: Shutterstock photo

Friday June 23 2017

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Oracle ( ORCL ), Allergan ( AGN ), and Abbott ( ABT ).These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Buy rated Oracle shares have outperformed the Zacks Technology Sector year-to-date, gaining +33.1% vs. +15.4%. The company's offerings in SaaS and PaaS have gained significant momentum in the past few quarters, which improves the company's competitive position in the red hot cloud space, particularly against salesforce.com and Workday. The Zacks analyst likes the company's growing cloud market share and sees the positive momentum in this area as a notable top-line growth driver. Moreover, Oracle continues to win new customers in HCM, ERP and CX. However, high investments in IaaS will affect gross margin expansion in the near-term. Further, a strong U.S. dollar remains a headwind.

(You can read the full research report on Oracle here >>> ) .

Shares of Allergan have gained +17.1% year to date, outperforming the Zacks Medical-Generic Drugs industry, which has increased +0.3% over the same period. The Zacks analyst likes products like Botox and Linzess as well as new products, which are supporting sales growth. With the closing of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent a significant opportunity. However, Allergan faces generic threats for legacy brands like Namenda IR as well as patent challenges for some of the other products in its branded portfolio. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern.

(You can read the full research report on Allergan here >>> ) .

Abbott 's shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +28.1% vs. +14.3% gain for the sector) on the back of greater appreciation for the company's strategic repositioning through acquisitions/divestitures. A case in point is the St. Jude Medical buyout that complements the company cardiovascular devices business. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. All in all, market participants like management's strategic focus on core therapeutic areas. On the flip side, the analyst identifies weakness in the nutrition business in China and sluggish growth in the Venezuelan market as areas of concern.

(You can read the full research report on Abbott here >>> ) .

Other noteworthy reports we are featuring today include Adobe ( ADBE ), Alexion ( ALXN ) and Valero ( VLO ).

Sell These Stocks. Now.

Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.

See today's Zacks "Strong Sells" absolutely free >>.

Brian Hamilton

Investment Research Coordinator

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Oracle (ORCL) Drives on Impressive SaaS and PaaS Growth

Allergan's (AGN) Key Drugs like Botox to Counter Generic Woes

Abbott (ABT) Up on St Jude Synergy & Newly Approved Devices

Featured Reports

Alexion (ALXN) Soliris Looks Strong, ALXN1210 in Focus

Alexion's blockbuster drug, Soliris, continues to perform while Kanuma lagged expectations. Per the Zacks analyst, the successful development of ALXN1210 will boost growth prospects significantly.

Valero (VLO) Refinery Base Diverse, Maintenance Cost High

While the covering analyst likes Valero's diversified refinery base and high dividend yield, its rise in expenses following heavy maintenance activities limits upside.

Cincinnati Bell (CBB) Gains Fioptics Users, Access Line Drops

Per the Zacks analyst, Fioptics internet and video subscriber gain is a major positive for Cincinnati Bell. However, loss in local access lines, heavy capital expenses and legal woes raises concerns.

Derivative Product Lines Aid CME Group (CME), High Costs Ail

The Zacks analyst thinks CME Group's focus on expansion of its derivative product lines will continue to drive growth.

Lululemon's (LULU) eCommerce Growth Efforts to Drive Sales

Per the covering analyst, Lululemon is capable of driving impressive sales growth by focusing on eCommerce and investing in innovation.

New Upgrades

Rising Deposits and Loans Support M&T Bank (MTB) Revenue

Per the Zacks analyst, organic growth remained a key strength at M&T Bank, as reflected by rising loans and deposits aiding revenue growth. Further, easing of margin pressure is a favorable factor.

Adobe (ADBE) Rides on Creative Cloud Business

With Adobe delivering strong Q2 results, the covering analyst believes that the company's strong position in creative cloud market and continued innovation will continue to drive growth going forward.

New Downgrades

Weakness in Print Operations to Dent John Wiley (JW.A) Sales

Per the Zacks analyst, John Wiley & Sons' top line is likely to be hurt as it continues to face weak demand for printed books. Evidently, revenues for publishing declined 7% in fiscal 2017.

Lennar (LEN) Q2 Gross Margin Suffers From Rising Land Costs

The covering analyst believes gross margin compression due to rising land and construction costs can keep the housing momentum in check. Lennar's gross margin declined 160 bps year over year in Q2.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Valero Energy Corporation (VLO): Free Stock Analysis Report

Oracle Corporation (ORCL): Free Stock Analysis Report

Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report

Allergan PLC. (AGN): Free Stock Analysis Report

Adobe Systems Incorporated (ADBE): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ORCL VLO ADBE ALXN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More